Small molecule · Antagonist of N-methyl-D-aspartate receptor · developed by Ph Health
Ketamine is a racemic, non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor. Its major metabolite, norketamine, has weaker activity at the same receptor.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Mar 27, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05907213 | Phase 1 | Pain, Postoperative | Completed | GRCE |
| NCT05049343 | Phase 1 | Healthy Volunteer | Completed | SUPN |
| NCT02611921 | Phase 1 | Autism Spectrum Disorder | Completed | ROIV |
| NCT04928703 | Early Phase 1 | Healthy | Completed | ALKS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Autism Spectrum DisorderDepression, PostpartumHealthyHealthy VolunteerPain, Postoperative
Updated Nov 1, 2026.